Related Experiment Video
Updated: Sep 14, 2025
Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
Therapeutic Potential of PDA@CeO2 in Suppressing Hepatic Stellate Cell Activation and Preventing Liver Fibrosis
Han-Mei Li1, Ju-Ying Zhang1, Xiao-Qing Wang1
1Department of Ultrasound, Affiliated Hospital of North Sichuan Medical College, Innovation Centre for Science and Technology of North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China.
Objective:
Liver fibrosis replaces healthy tissue with scar tissue, potentially leading to cirrhosis and cancer. ROS drive this process by activating hepatic stellate cells. This study tests the hepatoprotective effects of PDA@CeO2 nanoparticles in scavenging ROS, inhibiting HSC activation, and delaying fibrosis, using 2D-SWE to assess treatment efficacy.
Methods:
In vitro, flow cytometry evaluated ROS levels in HSCs, scratch assays assessed migration, and α-SMA expression confirmed activation. In vivo, PDA@CeO2 NPs were tested in rats with CCl4-induced liver fibrosis, with effects monitored by 2D-SWE. Histopathological staining and fibrosis markers (Collagen I, α-SMA, TGF-β/Smad3, NOX4) assessed fibrosis progression.
Results:
In vitro, PDA@CeO2 reduced ROS levels and inhibited HSC migration, with decreased α-SMA expression indicating suppressed activation. In vivo, PDA@CeO2 treatment in CCl4-induced liver fibrosis rats reduced fibrosis markers. 2D-SWE showed improved liver stiffness, and histopathological analysis revealed reduced fibrosis and inflammation. The therapeutic effects were linked to modulation of the NOX4-TGF-β/Smad3 pathway, attenuating fibrosis progression.
Conclusion:
This study demonstrates the potential of PDA@CeO2 NPs as a novel treatment for liver fibrosis. These nanoparticles scavenge ROS and modulate inflammatory pathways, targeting key signaling mechanisms like the NOX4-TGF-β/Smad3 pathway. PDA@CeO2 NPs offer a promising strategy for attenuating fibrosis at cellular and molecular levels. Additionally, 2D-SWE provides a non-invasive tool for monitoring therapeutic outcomes, positioning PDA@CeO2 NPs as a promising candidate for future clinical liver fibrosis treatments.
Insights
PDA@CeO2 nanoparticles show promise in treating liver fibrosis by reducing oxidative stress and inflammation. These nanoparticles effectively inhibit hepatic stellate cell activation and slow fibrosis progression, offering a novel therapeutic strategy.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Hepatology
Background:
- Liver fibrosis involves scar tissue replacing healthy liver tissue, potentially leading to cirrhosis and cancer.
- Reactive oxygen species (ROS) are key drivers of liver fibrosis by activating hepatic stellate cells (HSCs).
Purpose of the Study:
- To evaluate the hepatoprotective effects of PDA@CeO2 nanoparticles.
- To investigate the potential of these nanoparticles in scavenging ROS, inhibiting HSC activation, and delaying liver fibrosis.
- To assess treatment efficacy using 2D shear wave elastography (2D-SWE).
Main Methods:
- In vitro studies utilized flow cytometry for ROS levels and scratch assays for HSC migration, with α-SMA expression confirming activation.
- In vivo studies involved CCl4-induced liver fibrosis in rats treated with PDA@CeO2 NPs, monitored by 2D-SWE.
- Histopathological analysis and fibrosis markers (Collagen I, α-SMA, TGF-β/Smad3, NOX4) were used to assess fibrosis progression.
Main Results:
- PDA@CeO2 nanoparticles reduced ROS levels and HSC migration in vitro, suppressing α-SMA expression.
- In vivo, treatment decreased fibrosis markers, improved liver stiffness (2D-SWE), and reduced inflammation.
- Therapeutic effects were linked to modulation of the NOX4-TGF-β/Smad3 pathway, attenuating fibrosis.
Conclusions:
- PDA@CeO2 NPs demonstrate potential as a novel treatment for liver fibrosis by scavenging ROS and modulating inflammatory pathways.
- Targeting the NOX4-TGF-β/Smad3 pathway offers a strategy for attenuating fibrosis at cellular and molecular levels.
- 2D-SWE serves as a non-invasive tool for monitoring treatment outcomes, supporting PDA@CeO2 NPs for future clinical application.
